DNAPrint genomics Licenses Ritalin-Like Compounds Targeting Enhanced Treatment of Drug Addiction and Attention Deficit DNAPrint genomics, Inc. (OTC BB: DNAG) today announced it has licensed a series of methylphenidate analogs or Ritalin(TM)-like compounds targeting the clinical development of enhanced pharmaceuticals for the treatment of drug addiction, attention deficit hyperactivity disorder (ADHD), and depression. This is the second drug project that will be developed by DNAPrint Pharmaceuticals. Inc., the Company's wholly owned, recently formed pharmaceutical subsidiary focused on personalized medicine.
The licensed compounds are analogs of Ritalin(TM), a well-known drug used for treatment of ADHD. The analogs are designed specifically to have a slow onset and increased half-life in the blood stream, thus reducing a patient's required daily dosage and the potential for drug abuse.
Methylphenidate was first introduced in the 1940s for patients suffering from narcolepsy, a sleeping disorder. Methylphenidate later was found to be useful in treating hyperactive children and adults with depression. One of the drawbacks for methylphenidate is the requirement for multiple daily doses because the drug reaches peak plasma concentrations in two hours and the half-life is only one to three hours, with 80% of the drug excreted during urination. Dosing starts out low and is gradually escalated to a maximum of 60 mg per day for children.
"Our methylphenidate analogs are designed to treat depression and hyperactivity while reducing the required dosing and mitigating significantly the potential for abuse. Additionally, the compounds have potential as treatments for cocaine abuse. In fact, the National Institute for Drug Abuse is advancing one of the compounds in its search for pharmaco-therapies for cocaine abuse," said Dr. Mark Froimowitz, the leading researcher from whom the technology was licensed. "These compounds were designed using molecular modeling and synthesized in a process developed by Dr. Charles Kelley. This research has come out of 25 years of work in the fields of drug addiction, Parkinson's disease and ADHD."
Drs. Froimowitz and Kelley have applied for patents for the newly licensed compounds.
Ritalin(TM) or methylphenidate analogs represent a $4.6 billion dollar market opportunity by 2014, according to the consulting and research firm Decision Resources, Inc. "That's a significant opportunity for DNAPrint genomics and other drug developers," said Richard Gabriel, President and Chief Executive Officer of the Company. "The unique properties of these new compounds coupled with DNAPrint's expertise in determining the inherited gene characteristics of potential patients will enable us to target research on a drug for patients who respond positively to treatment, and hopefully, develop new compounds for those who might reject such a drug."
Dr. Froimowitz and DNAPrint genomics are also working with the National Institute for Drug Abuse (NIDA) in identifying compounds that offer potential relief to the craving usually associated with drug abuse.
"One of the underlying goals is to utilize the newly licensed Froimowitz analogs to develop drugs for patients who do not respond to methylphenidate treatment at all," said Dr. Hector J. Gomez, DNAPrint's Chief Medical Officer. "We are all very excited about combining our ability to identify responder and non-responder patients using genetic ancestry and other clinical markers and target clinical development programs toward those patients."
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Source: Market Wire (October 25, 2005 - 7:00 AM EDT)
getting some hits. lest see how it goes
Posted by Prdponce on :
moving
.0155 x .016
Posted by lilpennypincher on :
moving up now
Posted by Prdponce on :
yeap. it moves well on news
Posted by Prdponce on :
.0163 x .0164
Posted by lilpennypincher on :
Have to break that .0164!
Posted by Prdponce on :
yes that seems to be the resistance
Posted by lilpennypincher on :
couldn't break that .0164, here is the dip. If there is momo it may break it on the next run up.
Posted by Prdponce on :
if it does not do it now is all over. LOL
Posted by lilpennypincher on :
ging back up. Have to break .0164 on this one!
Posted by lilpennypincher on :
I'm out. Good luck all!
Posted by Prdponce on :
got out too.. NEXTTTTTTTT
Posted by Persia on :
DNAPrint genomics Receives Notice of Allowance for Patent for Processing Gene Sequence Data 10/27/05
SARASOTA, Fla., Oct 27, 2005 (PRIMEZONE via COMTEX) -- DNAPrint genomics, Inc. (OTCBB:DNAG), a developer of genomics-based products and services, today announced that it has been granted a notice of allowance from the U.S. Patent and Trademark Office for its patent application for Efficient Methods and Apparatus for High-Throughput Processing of Gene Sequence Data.
"Though we are all 99.9% identical at the level of our DNA, it is the 0.1% difference called polymorphism that accounts for our individuality," stated Tony N. Frudakis, Ph.D., DNAPrint's founder and Chief Scientific Officer. "The technology our patent application covers relates to methods useful for measuring polymorphisms in and around genes that are part of large gene families, a task that traditionally has been problematic for the molecular genetics community."
Geneticists use "molecular addresses" to query and study specific genes much like a postman uses a street address to find the recipient of a letter. The methods covered in the patent are useful when there are several genes with the same or substantially similar "sequence" addresses. Many of the genes that are involved in drug metabolism and response are members of large gene families.
This is the first patent for which the Company applied. The methods covered in the application, first drafted in 2001, were originally developed to power DNAPrint's unique approach to pharmacogenomics research, which is aimed at understanding why people respond uniquely to drugs.
About DNAPrint genomics, Inc.
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS, RETINOME, ANCESTRYbyDNA and EURO-DNA.
Posted by Persia on :
Maybe today is the day...
Posted by bmarley5780 on :
oversold... MACD looks to be goin to the right direction...
Posted by SFC_Jordan on :
SARASOTA, FL, Nov 01, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has acquired Kenna Technologies, Inc., of West Chester, Pa., a private company which builds computer models that mimic complex biological systems.
Under terms of the agreement, Kenna's shareholders exchanged all of the company's outstanding shares for 1.5 million shares of DNAPrint genomics Common Stock. The transaction was effective on Tuesday, Oct. 25, 2005.
"The acquisition of Kenna and its computational biology process, provides substantial synergies with our pharmacogenomics applications," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "We believe Kenna's technologies will lead to shorter and less expensive drug development times, and represent a powerful tool in our company's search to develop programs for personalized medicine, and test/drug combinations targeting a specific group of patients."
Computational biology models (also called In silico technology,) incorporate the vast datasets and fragmented knowledge of experimentalists and can be a crucial requirement when developing effective therapies and diagnostic products.
"Initially, the Kenna team will support the clinical development of DNAPrint's PT-401 Super EPO erythropoietin dimer for the treatment of anemia and renal failure," stated Kenna co-founder Barbara Handelin, Ph.D, who joins DNAPrint as Director of Diagnostics and General Manager of Computational Biology. "We will provide simulations to help design optimal clinical trials with respect to dosing, patient selection factors and trial duration."
As a result of the acquisition, DNAPrint also gains access to Kenna's BoneFusion(TM) and CellCycleFusion(TM) models. BoneFusion simulates the processes in bone remodeling that underlie diseases like osteoporosis, while CellCycleFusion simulates the molecular pathways that control basic cellular functions. These pathways are common targets of current cancer therapies.
"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in our Company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services focused on drug development, pharmacogenomic diagnostic tests, forensics technology and consumer genetic tests. The Company's first theranostic product (drug/test combination) is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Currently in pre-clinical development, PT-401 will be targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint's family of products for the law enforcement forensics and consumer markets include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward-Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact:
Richard Gabriel
President and CEO
941-366-3400
-or-
Ron Stabiner
The Wall Street Group, Inc.
212-888-4848
SOURCE: DNAprint Genomics, Inc.
Posted by Persia on :
DNAPrint Genomics Executives to Attend World Drug Discovery & Development Conference in Copenhagen 11/4/05
SARASOTA, FL, Nov 04, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it will be participating in the World Drug Discovery & Development Summit on Tuesday and Wednesday, Nov. 29-30, 2005 in Copenhagen, Denmark.
"The Summit comes at a time when DNAPrint genomics is actively pursuing the development of pharmacogenomic products that include test/drug combinations based on inherited gene characteristics. These test/drug combinations are designed to optimize patient response and improve efficacy," stated Hector J. Gomez, M.D., Ph.D., the Company's Chairman and Chief Medical Officer. "The Summit is an excellent opportunity to participate in targeted meetings with pharmaceutical industry representatives and to discuss our Company's advances in the field of personalized medicine."
Other top DNAPrint executives attending the summit, which is sponsored by the London-based World Trade Group, are President and Chief Executive Office Richard Gabriel and Company Founder and Chief Scientific Officer Tony N. Frudakis.
"This conference presents us a forum to showcase not only our drug development, but also how our technologies, products and services can help the pharmaceutical companies accelerate their own research and development programs," Mr. Gabriel said.
"The development of pharmaceuticals that improve the quality of life for medical patients has been an over-riding goal of our Company from its beginning," Dr. Frudakis stated. "Our research in drug development is well under-way and our newly formed DNAPrint Pharmaceutical subsidiary emphasizes the importance we place on this objective."
Posted by Persia on :
190 x 192
Posted by Persia on :
194 x 195
Posted by Persia on :
197 x 198
Posted by Persia on :
204 x 205
It's going up boys and girls.
Posted by Persia on :
209 x 210
Flying! Posted by Persia on :
213 x 217
Posted by Persia on :
A first dip here.
Posted by SFC_Jordan on :
Big boys are selling, im out at .0215
Posted by Persia on :
Out at 213.
Nice run to start the day with.
Posted by BigBuyer100 on :
Motge is going to run soon.
Posted by matto on :
still in and running this till it hits 40%
Posted by SFC_Jordan on :
Matto, great job. you brave sole you. LOL
Posted by tara81662l on :
Just saw this. More people hearing about DNAG!
OTC ADVISORS, LLC: www.otc-advisors.com "BULLS IN THE STABLE" CEOA, DNAG, IVCM, MOBL
By M2 Last Update: 11/4/2005 10:33:23 AM Data provided by
NY, Nov 04, 2005 (M2 PRESSWIRE via COMTEX) -- www.otc-advisors.com "Bull's in the stable" CEO America, Inc. (CEOA), DNAPrint(TM)genomics, Inc. (DNAG),IVI Communications Inc. (IVCM) and MobilePro Corp. (MOBL)
Posted by Malloy on :
No. 1 traded OTC penny today...this one,s hot.
Posted by Malloy on :
Going to test hod again...still on the top listed trading stocks today.
Posted by kilerb on :
Where do you guys seeing this one going? Is it just having it's day in the sun because of news and then it's bye bye again?
Posted by Malloy on :
Trying to break hod at .023 during lunch.
kilerb, with this kind of volume, should be a good play for a couple days. This is OTC land, anything can happened, be quick to react that's the only advice I can tell you.
Posted by SFC_Jordan on :
I did get out of this earlier, but still watching, but if ARCA stops sqrewing with you guys, it should go a bit higher.
Posted by matto on :
almost at my 40% go baby go!
Posted by SFC_Jordan on :
ARCA, TRAC, NITE, and FLCR are playing, be careful my RI friend.
Posted by Superbee383 on :
Have you noticed how many times the Bid and Ask were the same? And a few times where the bid was higher than the ask? What does that usually mean? That they need shares?
Posted by SFC_Jordan on :
Not sure, but the big MM's sqrewed it up for the people who were still in for today.
Posted by gohigh on :
A little profit taking there at the end. Does it settle down on Monday or go a little higher? Any thoughts?
Posted by wantmoneyabc on :
with my luck, it will go dow and up all day... just like I like it.. up down up down up down...
get it.
Posted by Malloy on :
Gapping and premarket buys.
The key is to break .023 for another great day.
Posted by gohigh on :
Yeah, I still got it. Hopefully, it will go back up. Seems like a cutting edge company selling at a bargain price.
Posted by Malloy on :
Finally found bottom. NITE walked it down to .016 but someone's buying big block of this.
They might be shaking weak hands for next PR.
Posted by Malloy on :
Nice bounce now back over .017
Posted by marcinek on :
Wow. Painful today. You guys think this is good entry?
Posted by Persia on :
DNAPrint Pharmaceuticals to Combine Computer Modeling With Genetics to Improve Drug Development 11/8/2005
SARASOTA, FL, Nov 08, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) today announced that DNAPrint Pharmaceuticals, Inc.'s Computational Biology Division, which was recently acquired from Kenna Technologies, Inc., is preparing to launch its services contract business for the pharmaceutical and biotechnology industries.
By incorporating DNAPrint's pharmacogenomics contract services with those of the Computational Biology Division, the end result will be a unique solution for optimizing clinical trials. DNAPrint will demonstrate to drug developers that they can learn more about a new drug's patient benefit as well as an optimum dosing regimen.
The computational biology scientists at DNAPrint Pharmaceuticals have developed a system for analyzing complex biological processes. "Our offering is pragmatic," says Dr. Barbara Handelin, General Manager of Computational Biology. "Even with an imperfect understanding of disease and human physiology, we have shown that we can create highly predictive models that improve the understanding of researchers. We are especially excited to demonstrate to potential clients how modeling can work synergistically with genetic studies of drug response."
DNAPrint genomics utilizes a proprietary technology that measures variations among patient populations that relate to their responses to drugs. The combination of the two technologies will assist developers of pharmaceutical products in identifying important patient factors that impact how a specific drug will affect different groups of patients. Some of these factors are inborn, such as genetic markers; others are identified by the Company's computer simulations, which will be inherent to the role of the drug in the disease under treatment. The Company will also help identify genetic and other patient factors predisposing patients to toxic side effects.
DNAPrint also uses simulations to model the molecular and cellular effects of a drug candidate so that researchers can ask many more "what if" questions about dose levels and scheduling as opposed to actual human or animal studies. These simulations then guide the design of actual clinical trials with advanced "intelligence" about the likely outcomes. The likelihood of successful trials, targeted to the right patients with an effective dosing regimen is greatly enhanced; and could lead to reduced time and costs of clinical studies.
"We invite everyone to use our services," said Hector J. Gomez, M.D., Ph.D., DNAPrint's Chairman and Chief Medical Officer. "We believe that bringing computer modeling and genetics together is a natural fit for optimizing drug discovery and development. These are independent approaches that together start to improve preclinical and clinical development from strictly empirical medicinal chemistry trials to mechanistically driven human biology studies."
"Simply put, DNAPrint will utilize computational modeling to develop drugs more efficiently," said DNAPrint President and Chief Executive Officer Richard Gabriel. "It will play a valuable role in any company's efforts to pursue the development of drugs which maximize efficacy and minimize side effects by tailoring medications for specific individuals and well-defined population sectors."
Posted by Malloy on :
News...what a surprise after MM walked the price down yesterday :-)
Posted by Malloy on :
Here we go...
Posted by Malloy on :
About to hit .019 and we haven't seen the big volume yet :-)
Posted by Malloy on :
About to hit .02 :-)
Posted by Malloy on :
At .021 :-)
Posted by Malloy on :
Building very nice support at .02
Afternoon should be good for second run.
Posted by Malloy on :
Gapping up again this morning.
Posted by Malloy on :
DNAPrint Genomics and SeraCare's Genomics Collaborative Combine to Improve Outcome for Ovarian Cancer Treatment
Monday , November 14, 2005 07:00 ET
SARASOTA, FL AND OCEANSIDE, CA, Nov 14, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG) and the Cambridge, Mass.-based Genomics Collaborative Division of SeraCare Life Sciences, Inc., today announced that they have begun collaboration on a project designed to improve treatment for patients with ovarian cancer.
"The goal is to identify genetic factors that will enable physicians to predict the outcome and efficacy of carboplatin/tamoxifen treatment, a standard therapy for victims of breast cancer," stated Hector J. Gomez, M.D., Ph.D., Chairman and Chief Medical Officer of DNAPrint genomics. "Combining Genomics Collaborative's extensive network of physician-managed centers with DNAPrint's proprietary genetic testing, the genetic characteristics of 200 women will be studied by comparing those who responded to a standard carboplatin/tamoxifen regimen for breast cancer with those who did not."
"We anticipate that the study's findings may enable physicians to identify likely non-responders before initiation of carboplatin/tamoxifen therapy so that an alternative treatment can be utilized from the outset," stated Kevin Krenitsky, M.D., Senior Vice President and Division Head of Genomics Collaborative. "We hope to improve the outcome of treatment for patients afflicted with this challenging condition."
This marks the second collaborative project between DNAPrint and Genetics Collaborative.
About SeraCare Life Sciences
SeraCare Life Sciences, Inc. is a manufacturer and supplier of biological materials and services essential for the use and manufacture of diagnostic tests and the discovery, development and commercial production of pharmaceuticals. The Company's offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and the Global Repository(R), comprised of clinical samples (DNA, RNA, tissue, and serum) for use in the drug discovery and development processes. SeraCare is headquartered in Oceanside, CA, and maintains facilities in Cambridge and West Bridgewater, MA; Frederick and Gaithersburg, MD; and Hatboro, PA. For more information please visit http://www.seracare.com.
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2005 Market Wire, All rights reserved
Posted by Malloy on :
More good news today.
DNAPrint genomics to Acquire Ellipsis Biotherapeutics
Tuesday , November 15, 2005 07:00 ET
SARASOTA, FL, Nov 15, 2005 (MARKET WIRE via COMTEX) -- DNAPrint(TM) genomics, Inc. (OTC BB: DNAG), a developer of genomics-based products and services, today announced that it has entered into an agreement to acquire the clinical genomics and genotyping assets of Ellipsis Biotherapeutics Corporation ("Ellipsis"), a privately held drug and diagnostic discovery company based in Toronto, Canada.
Under terms of the agreement, Ellipsis is selling these core assets for 6,500,000 shares of DNAPrint genomics common stock. Pending completion of DNAPrint due diligence and Ellipsis shareholder approval, the transaction is expected to be completed by Nov. 30, 2005. DNAPrint will retain Ellipsis' employees, management and business operations. In addition, DNAPrint will retain the Ellipsis Biotherapeutics name and operate Ellipsis Biotherapeutics as a subsidiary of DNAPrint genomics.
"Ellipsis has developed novel drug technologies and has spun those operations out," stated Hector J. Gomez, M.D., Ph.D., DNAPrint Chairman and Chief Medical Officer and head of its wholly owned DNAPrint Pharmaceuticals, Inc. subsidiary. "The value for DNAPrint is that Ellipsis' platform technology is highly compatible with our mission to expand our capabilities and increase our revenues."
Richard Gabriel, DNAPrint President and Chief Executive Officer, noted that DNAPrint is actively involved in development of pharmacogenomics through in-house research, licensing agreements and the acquisition of synergistic technologies, all targeting future growth for the Company. "Our recent acquisition of Kenna Technologies, which builds computer models that mimic complex biological systems, as well as Ellipsis' synergistic gene platform applications, will broaden our capabilities and add to the growing number of products in our pipeline."
Ellipsis is located in downtown Toronto adjacent to the academic health science complex and major teaching hospitals. Using the Beckman Coulter GenomeLab SNPstream and the Illumina Beadstation, Ellipsis performs contract SNP genotyping for academic centers, hospitals, human health care corporations and biotech companies. Its diverse services include human, plant and animal analyses.
"We are very excited to become part of the DNAPrint group of companies," stated Dr. Laurence Rubin, Chief Executive Officer of Ellipsis. "Our core competencies provide a unique fit for the future growth and development of our contract services as well as opportunity to participate in novel research programs and collaborations."
About DNAPrint
DNAPrint genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM).
Forward Looking Statements
All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
Company Contact: Richard Gabriel President and CEO 941-366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
![[Smile]](smile.gif)